Tech Company Financing Transactions

NanoPhoria Bioscience Funding Round

On 10/6/2025, NanoPhoria Bioscience received $97 million in Series A funding from CDP Venture Capital, Sofinnova Partners and XGen Ventures.

Transaction Overview

Announced On
10/6/2025
Transaction Type
Venture Equity
Amount
$97,000,000
Round
Series A
Investors

CDP Venture Capital (Lead Investor)

Sofinnova Partners (Lead Investor)

XGen Ventures (Lead Investor)

Panakes Partners

Proceeds Purpose
The company intends to use the funds to propel its lead candidate, NP-MP1, through IND-enabling studies and early clinical development. It is a first-in-class peptide that targets cardiac L-type calcium channels to improve ejection fraction for the treatment of heart failure with reduced ejection fraction (HFrEF).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Via Visconti di Modrone, 18
Milan, 20122
Italy
Phone
Undisclosed
Email Address
Overview
NanoPhoria is a preclinical stage biotech company pioneering inhalable cardiovascular treatments via non-viral nano-delivery of biologics. The Company is devoted to the clinical development of an innovative proprietary platform for the tissue-directed delivery of therapeutic peptides and RNAs. The core vehicle is an inorganic calcium-phosphate nanoparticle which represents a versatile, biomimetic nano-carrier that can be loaded or surface decorated with biologics and can be formulated for inhalation or for other administration routes.
Profile
NanoPhoria Bioscience LinkedIn Company Profile
Social Media
NanoPhoria Bioscience Company Twitter Account
Company News
NanoPhoria Bioscience News
Facebook
NanoPhoria Bioscience on Facebook
YouTube
NanoPhoria Bioscience on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Claudio De Luca
  Claudio De Luca LinkedIn Profile  Claudio De Luca Twitter Account  Claudio De Luca News  Claudio De Luca on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/6/2025: Filigran venture capital transaction
Next: 10/6/2025: Agio Ratings venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to document every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary